上海交通大学学报（医学版）

›› 2010, Vol. 30 ›› Issue (3): 271-.

• 专题报道（甲状腺癌核素治疗） • 上一篇    下一篇

分化型甲状腺癌131I治疗对患者肝肾功能的影响

吴书其1, 李 瑾2, 叶智轶1, 冯 方1, 吴震宇1, 李佳宁1, 傅宏亮1, 邹仁健1, 王 辉1   

  1. 1. 上海交通大学 医学院新华医院核医学科, 上海 200092；2. 上海长征医院肾内科, 上海 200003
  • 出版日期:2010-03-25 发布日期:2010-03-24
  • 通讯作者: 王 辉, 电子信箱: wanghuishanghai@hotmail.com。
  • 作者简介:吴书其(1982—), 男, 住院医师, 硕士；电子信箱: royewuhao@gmail.com。
  • 基金资助:

    上海市重点学科建设项目（S30203）

Effects of 131I therapy for differentiated thyroid carcinoma on liver and renal function

WU Shu-qi1, LI Jin2, YE Zhi-yi1, FENG Fang1, WU Zhen-yu1, LI Jia-ning1, FU Hong-liang1, ZOU Ren-jian1, WANG Hui1   

  1. 1. Department of Nuclear Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200092, China；2. Department of Nephrology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
  • Online:2010-03-25 Published:2010-03-24
  • Supported by:

    Shanghai Leading Academic Discipline Project, S30203

PDF (PC)

1533

摘要：

目的 研究应用放射性碘（131I）治疗分化型甲状腺癌（DTC）对患者肝肾功能的影响。方法 收集接受131I 治疗的106例DTC患者的临床资料，并根据131I治疗剂量分为低剂量组（≤1.85 GBq，n=19）、中剂量组（2.22 GBq和2.96 GBq，n=50）和高剂量组（≥3.7 GBq，n=37）。对实施131I 治疗前后及各组患者的肝肾功能检查结果进行对比分析。结果 接受131I 治疗前后，67例患者肝功能检查结果记录完整（低剂量组18例，中剂量组37例，高剂量组12例）。与治疗前比较，治疗后总体血清谷草转氨酶（AST）和谷丙转氨酶（ALT）水平升高（P<0.05），但大部分（82.1%）仍在正常范围内。接受131I 治疗前后，106例患者均具有完整的肾功能检查结果记录。组内治疗前后患者血尿素氮（BUN）、肌酐（SCr）、尿酸（UA）水平比较，差异均无统计学意义（P>0.05）。结论 131I治疗DTC对患者肝肾功能无明显影响，是较为安全的治疗方法。

关键词: 放射性碘, 分化型甲状腺癌, 肝功能, 肾功能

Abstract:

Objective To investigate the effects of radioactive iodine (131I) therapy for differentiated thyroid carcinoma (DTC) on liver and renal function. Methods The clinical data of 106 patients with DTC were collected, and patients were divided into low dose group (≤1.85 GBq, n=19), middle dose group (2.22 GBq and 2.96 GBq, n=50) and high dose group (≥3.7 GBq, n=37) according to 131I doses. The results of liver and renal examinations were compared and analysed before and after 131I therapy among groups. Results The data of liver function were complete in 67 patients before and after 131I therapy (low dose group, n=18; middle dose group, n=37; high dose group, n=12). Compared with those before treatment, the total aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were higher (P<0.05), while the AST and ALT levels of the majority (82.1%) were in the normal ranges. The data of renal function were complete in all the 106 patients before and after 131I therapy. There was no significant difference in blood urea nitrogen (BUN), serum creatinine (SCr) and uric acid (UA) before and after treatment in each group (P>0.05). Conclusion 131I therapy is safe for DTC, with no significant effect on liver and renal function.

Key words: radioactive iodine, differentiated thyroid carcinoma, liver function, renal function